QL1706 (PD-1/CTLA-4 bispecific antibody)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for QL1706 (PD-1/CTLA-4 bispecific antibody), covering 2025-05-22 to 2025-05-22. Get the full timeline:
Most recent: Clinical Trial Update: QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. [Phase 3]